4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
6.31
+0.53 (9.17%)
At close: Dec 20, 2024, 4:00 PM
6.62
+0.31 (4.91%)
After-hours: Dec 20, 2024, 4:16 PM EST
4D Molecular Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 0.02 | 20.72 | 3.13 | 18.04 | 13.61 | 6.99 | |
| Revenue Growth (YoY) | -99.92% | 562.29% | -82.65% | 32.52% | 94.85% | -50.56% | |
| Cost of Revenue | 124.24 | 97.1 | 80.25 | 61.36 | 53.04 | 38.72 | |
| Gross Profit | -124.22 | -76.37 | -77.12 | -43.32 | -39.43 | -31.73 | |
| Selling, General & Admin | 44.15 | 36.49 | 32.91 | 28.01 | 17.24 | 13.9 | |
| Operating Expenses | 44.15 | 36.49 | 32.91 | 28.01 | 17.24 | 13.9 | |
| Operating Income | -168.38 | -112.87 | -110.03 | -71.33 | -56.66 | -45.63 | |
| Interest & Investment Income | 24.96 | 12.21 | 2.57 | 0.14 | 0.15 | 1.5 | |
| Other Non Operating Income (Expenses) | -0.07 | -0.18 | -0.04 | -0.12 | -0.18 | -0.05 | |
| EBT Excluding Unusual Items | -143.48 | -100.84 | -107.49 | -71.32 | -56.69 | -44.17 | |
| Pretax Income | -143.48 | -100.84 | -107.49 | -71.32 | -56.69 | -49.31 | |
| Net Income | -143.48 | -100.84 | -107.49 | -71.32 | -56.69 | -49.31 | |
| Net Income to Common | -143.48 | -100.84 | -107.49 | -71.32 | -56.69 | -49.31 | |
| Shares Outstanding (Basic) | 51 | 39 | 32 | 28 | 6 | 5 | |
| Shares Outstanding (Diluted) | 51 | 39 | 32 | 28 | 6 | 5 | |
| Shares Change (YoY) | 38.91% | 20.95% | 16.66% | 331.23% | 25.05% | 1.85% | |
| EPS (Basic) | -2.83 | -2.58 | -3.32 | -2.57 | -8.82 | -9.59 | |
| EPS (Diluted) | -2.83 | -2.58 | -3.32 | -2.57 | -8.82 | -9.59 | |
| Free Cash Flow | -116.76 | -78.56 | -98.22 | -78.24 | -51.91 | -39.91 | |
| Free Cash Flow Per Share | -2.30 | -2.01 | -3.04 | -2.82 | -8.07 | -7.76 | |
| Gross Margin | - | - | - | -240.17% | -289.64% | - | |
| Operating Margin | -990447.06% | -544.65% | -3516.52% | -395.46% | -416.28% | -653.12% | |
| Profit Margin | -844000.00% | -486.59% | -3435.41% | -395.37% | -416.49% | -705.78% | |
| Free Cash Flow Margin | -686811.76% | -379.11% | -3139.05% | -433.77% | -381.35% | -571.34% | |
| EBITDA | -163.72 | -108.66 | -107.63 | -69.81 | -55.22 | -44.62 | |
| D&A For EBITDA | 4.66 | 4.2 | 2.4 | 1.52 | 1.44 | 1 | |
| EBIT | -168.38 | -112.87 | -110.03 | -71.33 | -56.66 | -45.63 | |
| Revenue as Reported | - | - | - | - | 13.61 | 6.99 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.